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Special proresolving mediators (SPMs) limit the intensity of inflammation; however, their regulation is poorly
understood. In this issue of Immunity, Li et al. (2013) describe bipolar roles for miR-466l in the promotion of
inflammation and the induction of SPMs.Charles Serhan and his group have made
major contributions related to functions of
lipid-derivedmediators (resolvins, special-
ized proresolving mediators [SPMs]) that
limit the duration and magnitude of the
acute inflammatory response (collectively
termed resolution) (Serhan, 2009; Serhan
et al., 2008). Resolution is linked to
programmed events designed to contain
the inflammatory response before serious
tissue injury occurs. SPMs (such as
lipoxins, resolvins, protectins, and mare-
sins) reduce leukocyte trafficking into
tissues and have proresolving functions
that enhance macrophage clearance of
apoptotic neutrophils (PMNs) and
microbes. Precise details of how these
lipids function is not known. Issues that
deserve study are the extent to which re-
ceptors for these lipids are similar to those
identified for leukotrienes and other arach-
idonate products. The signaling events
in leukocytes for responses to resolvins
should be studied. Such information could
set the pharmacological basis for manipu-
lation that positively or negatively affects
outcomes of the resolution phase of
inflammation.
In the accompanying report by Li et al.
(2013), miR-466l, a microRNA, was found
in blood of mice in an acute sepsis model
(after intraperitoneal injection of zymosan
particles, which are glycans derived
from fungi and reactive with TLR2). It
is suggested that miR-466l may play
a role in initiation of the acute inflamma-
tory response. Zymosan instillation intra-
peritoneally induced intense peritoneal
and systemic inflammatory responses
(defined by cytokine or chemokine
appearance) and recruitment of neutro-
phils (PMNs) followed by macrophages
and monocytes. miR-466l amounts were
highest in the early phases of responses
to zymosan particles, probably being pro-
duced by PMNs. Soon thereafter followedthe production of resolvins and maresins,
which have a variety of effects that
restrain the inflammatory response (Re-
cchiuti and Serhan, 2012; Serhan, 2009).
These lipid products facilitated macro-
phage uptake of apoptotic PMNs, result-
ing in quelling of the inflammatory
response. The model in its early phases
also caused increased amounts of the
vascular adhesion molecules, ICAM-1
and P-selectin (on endothelial cells),
which facilitate leukocyte recruitment
into the inflamed peritoneum. Overex-
pression of miR-466l in PMNs promoted
initiation of the inflammatory response,
whereas overexpression in macrophages
accelerated resolution of inflammation.
Such outcomes appeared to be linked to
enhanced levels of cyclooxygenase-2
and 15-lipoxygenase, resulting in more
prostanoids and SPMs. Precise details
of molecular events triggered by miR-
466l in PMNs and macrophages are not
known.
As implied above, miR-466l promoted
expression of lipid mediators (SPMs),
which include resolvins and maresins,
resulting in enhanced macrophage up-
take of apoptotic neutrophils (PMNs),
effectively quenching the inflammatory
response. The process of macrophage
phagocytosis of apoptotic PMNs has
been described as ‘‘efferocytosis’’ (Korns
et al., 2011). Such events are considered
important for termination of the acute
inflammatory response, allowing return of
the tissue to the preinflammatory state.
Efferocytosis prevents apoptotic PMNs
from releasing tissue-damaging factors
into nearby tissues. The authors also pro-
vide evidence that miR-466l was present
in the blood of septic humans, possibly
representing a new biomarker for sepsis,
but these data are preliminary (see below).
On the basis of the new report (Li et al.,
2013), one can postulate the followingImmunity 39, Nsequence of molecular events involved
in biological responses in sepsis or in
sepsis-like conditions (Figure 1). A similar
series of events occurs after microbial
sepsis (bacterial, fungal, viral) or after
‘‘sterile sepsis’’ such as that following
acute liver injury induced by acetamino-
phen (Xu et al., 2011) or tissue injury
after ischemia-reperfusion (Eltzschig and
Eckle, 2011) or hemorrhagic shock (Lo-
mas-Niera et al., 2005).Microbial-induced
sepsis is often initiated by release from in-
fectious agents of ‘‘pathogen-associated
molecular patterns’’ (PAMPs), such as
lipopolysaccharides that react with toll-
like receptor-4 (TLR4). ‘‘Sterile sepsis’’
is associated with release of ‘‘danger-
associated molecular patterns’’ (DAMPs),
such as ATP, mitochondrial DNA, extra-
cellular histones, which interact with
TLR2, TLR4, and NOD receptors (Xu
et al., 2009). The presence of microbial-
or host-derived products triggers acti-
vation of signaling pathways (via PI3k,
MAPKs), resulting in a ‘‘cytokine storm’’
that is often followedby septic shock,mul-
tiorgan failure, and lethality. It is possible
that miR-466l play key roles in initiation
of these cascades. The identification of re-
solvins and maresins (Li et al., 2013; Ser-
han et al., 2008) has suggested that these
lipid products are key for resolution of
the acute inflammatory response. The first
part of the acute inflammatory response
features the buildup of PMNs locally in
tissues. There is emerging evidence that
formation of extracellular histones may
be key in triggering the acute inflammatory
responses in experimental sepsis in mice
(endotoxemia or cecal ligation and punc-
ture) (Xu et al., 2009). Based on the
new data, miR-466l appears early in the
initiation phase of inflammation and may
derive from PMNs, whereas the resolution
phase of the inflammatory response fea-
tures monocytes and macrophages, bothovember 14, 2013 ª2013 Elsevier Inc. 801
Figure 1. Initiation and Resolution of
Inflammation in Sepsis
The inflammatory cascade occurs after initiation of
sepsis resulting from either noninfectious condi-
tions (e.g., hemorrhagic shock, trauma, chemical
injury of liver) or contact with infectious agents
(bacterial, viral, fungal). Such settings initiate an
acute inflammatory response, featuring tissue
buildup of PMNs, proinflammatory mediators,
and increased presence of vascular adhesion mol-
ecules that promote influx of PMNs and mono-
cytes. Li et al. (2013) report the appearance of
miR-466l in blood from mice with the zymosan-
induced model of sepsis. miR-466l promotes
the acute inflammatory response, whereas resolu-
tion of the inflammatory response features tissue
buildup of monocytes and macrophages, along
with resolvins and maresins, which, with miR-
466l, promote macrophage phagocytosis and
removal of apoptotic PMNs, leading to termination
of the inflammatory response. Septic humans have
presence of miR-466l in their blood.
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Previewsof which producemiR-466l. miR-466l also
appears to regulate transcription factors
(AP-1, NF-kB1). As noted above, produc-
tion of resolvins and maresins reinforces802 Immunity 39, November 14, 2013 ª2013efferocytosis by tissue macrophages, re-
sulting in resolution of the inflammatory
response. Although miR-466l has been
found in the blood of patients with sepsis,
it is too early to know the significance of
such data.
Several issues deserve additional
consideration. Preliminary data in Table 1
of Li et al. (2013) suggest the appearance
of miR-466l in blood from septic patients
(with E. coli infections), but there are insuf-
ficient numbers of patients (<10 in each of
3 groups) for definitive conclusions. Addi-
tional recruitment of individuals in various
stages of sepsis (sepsis, severe sepsis,
septic shock, and multiorgan failure) are
needed, classified according to estab-
lished consensus criteria (Levy et al.,
2003). The presence or absence of miR-
466l as well as resolvins and maresins
could be assessed, together with other
biomarkers, which are displayed in
Table 1. Since the data from Table 1
were from patients with E. coli infections,
it would be informative to similarly assess
septic patients with Gram-positive infec-
tions. It would also be useful to assess in-
dividuals with ‘‘sterile sepsis’’ (see text
and Table 1 of Li et al., 2013, and Figure 1)
in order to determine whether miR-466l
and SPM presence extends to these
noninfectious types of sepsis. Finally,
investigating the role of SPMs and miR-
466l in humanswith autoimmunediseases
might yield information about why these
disorders are nonresolving inflammatory
disorders.
It seems increasingly likely that miRs
and lipid mediators will be found to play
important roles not only in sepsis butElsevier Inc.also in a variety of other inflammatory
responses. It will be interesting to watch
these events unfold as their application
to humans becomes a reality. In the
meantime, this study provides an inter-
esting peek into a microRNA whose
mood disorder leads to tissue destruction
that is eventually salvaged by an about
face resulting in restitution.REFERENCES
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